Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilities cell-cell adhesion

Hitomi Tsuji, Seiichi Takasaki, Michiie Sakamoto, Tatsuro Irimura, Setsuo Hirohashi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Recently, we identified dysadherin, a novel carcinoma-associated glycoprotein, and showed that overexpression of dysadherin in human hepatocarcinoma, PLC/PRF/5 cells could suppress E-cadherin-mediated cell-cell adhesion and promote tumor metastasis. The present study shows evidence that dysadherin is actually O-glycosylated. This was based on a direct carbohydrate composition analysis of a chimera protein of an extracellular domain of dysadherin fused to an Fc fragment of immunoglobulin. To assess the importance of O-glycosylation in dysadherin function, dysadherin-transfected hepatocarcinoma cells were cultured in a medium containing benzyl-α-GalNAc, a modulator of O-glycosylation. This treatment facilitated homotypic cell adhesion among dysadherin transfectants accompanied with morphological changes, indicating that the anti-adhesive effect of dysadherin was weakened. Modification of O-glycan synthesis also resulted in down-regulation of dysadherin expression and up-regulation of E-cadherin expression in dysadherin transfectants but did not affect E-cadherin expression in mock transfectants. Structural analysis of O-glycans released from the dysadherin chimera proteins indicated that a series of O-glycans with core 1 and 2 structures are attached to dysadherin, and their sialylation is remarkably inhibited by benzyl-α-GalNAc treatment. However, sialidase treatment of the cells did not affect calcium-dependent cell aggregation, which excluded the possibility that sialic acid itself is directly involved in cell-cell adhesion. We suggest that aberrant O-glycosylation in carcinoma cells inhibits stable expression of dysadherin and leads to the up-regulation of E-cadherin expression by an unknown mechanism, resulting in increased cell-cell adhesion. The carbohydrate-directed approach to the regulation of dysadherin expression might be a new strategy for cancer therapy.

Original languageEnglish
Pages (from-to)521-527
Number of pages7
JournalGlycobiology
Volume13
Issue number7
DOIs
Publication statusPublished - 2003 Jul 1
Externally publishedYes

Fingerprint

Tumor-Associated Carbohydrate Antigens
Glycosylation
Cell adhesion
Cadherins
Cell Adhesion
Polysaccharides
Cells
Carbohydrates
Immunoglobulin Fc Fragments
Neuraminidase
N-Acetylneuraminic Acid
Up-Regulation
Programmable logic controllers
Structural analysis
Modulators
Carcinoma
Tumors
Adhesives
Cell Aggregation
Glycoproteins

Keywords

  • Benzyl-α-Ga1NAc
  • Cell-cell adhesion
  • Dysadherin
  • E-cadherin
  • O-glycosylation

ASJC Scopus subject areas

  • Biochemistry

Cite this

Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilities cell-cell adhesion. / Tsuji, Hitomi; Takasaki, Seiichi; Sakamoto, Michiie; Irimura, Tatsuro; Hirohashi, Setsuo.

In: Glycobiology, Vol. 13, No. 7, 01.07.2003, p. 521-527.

Research output: Contribution to journalArticle

Tsuji, Hitomi ; Takasaki, Seiichi ; Sakamoto, Michiie ; Irimura, Tatsuro ; Hirohashi, Setsuo. / Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilities cell-cell adhesion. In: Glycobiology. 2003 ; Vol. 13, No. 7. pp. 521-527.
@article{d87389305cf5486ba597b78a7b2ba2e1,
title = "Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilities cell-cell adhesion",
abstract = "Recently, we identified dysadherin, a novel carcinoma-associated glycoprotein, and showed that overexpression of dysadherin in human hepatocarcinoma, PLC/PRF/5 cells could suppress E-cadherin-mediated cell-cell adhesion and promote tumor metastasis. The present study shows evidence that dysadherin is actually O-glycosylated. This was based on a direct carbohydrate composition analysis of a chimera protein of an extracellular domain of dysadherin fused to an Fc fragment of immunoglobulin. To assess the importance of O-glycosylation in dysadherin function, dysadherin-transfected hepatocarcinoma cells were cultured in a medium containing benzyl-α-GalNAc, a modulator of O-glycosylation. This treatment facilitated homotypic cell adhesion among dysadherin transfectants accompanied with morphological changes, indicating that the anti-adhesive effect of dysadherin was weakened. Modification of O-glycan synthesis also resulted in down-regulation of dysadherin expression and up-regulation of E-cadherin expression in dysadherin transfectants but did not affect E-cadherin expression in mock transfectants. Structural analysis of O-glycans released from the dysadherin chimera proteins indicated that a series of O-glycans with core 1 and 2 structures are attached to dysadherin, and their sialylation is remarkably inhibited by benzyl-α-GalNAc treatment. However, sialidase treatment of the cells did not affect calcium-dependent cell aggregation, which excluded the possibility that sialic acid itself is directly involved in cell-cell adhesion. We suggest that aberrant O-glycosylation in carcinoma cells inhibits stable expression of dysadherin and leads to the up-regulation of E-cadherin expression by an unknown mechanism, resulting in increased cell-cell adhesion. The carbohydrate-directed approach to the regulation of dysadherin expression might be a new strategy for cancer therapy.",
keywords = "Benzyl-α-Ga1NAc, Cell-cell adhesion, Dysadherin, E-cadherin, O-glycosylation",
author = "Hitomi Tsuji and Seiichi Takasaki and Michiie Sakamoto and Tatsuro Irimura and Setsuo Hirohashi",
year = "2003",
month = "7",
day = "1",
doi = "10.1093/glycob/cwg065",
language = "English",
volume = "13",
pages = "521--527",
journal = "Glycobiology",
issn = "0959-6658",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilities cell-cell adhesion

AU - Tsuji, Hitomi

AU - Takasaki, Seiichi

AU - Sakamoto, Michiie

AU - Irimura, Tatsuro

AU - Hirohashi, Setsuo

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Recently, we identified dysadherin, a novel carcinoma-associated glycoprotein, and showed that overexpression of dysadherin in human hepatocarcinoma, PLC/PRF/5 cells could suppress E-cadherin-mediated cell-cell adhesion and promote tumor metastasis. The present study shows evidence that dysadherin is actually O-glycosylated. This was based on a direct carbohydrate composition analysis of a chimera protein of an extracellular domain of dysadherin fused to an Fc fragment of immunoglobulin. To assess the importance of O-glycosylation in dysadherin function, dysadherin-transfected hepatocarcinoma cells were cultured in a medium containing benzyl-α-GalNAc, a modulator of O-glycosylation. This treatment facilitated homotypic cell adhesion among dysadherin transfectants accompanied with morphological changes, indicating that the anti-adhesive effect of dysadherin was weakened. Modification of O-glycan synthesis also resulted in down-regulation of dysadherin expression and up-regulation of E-cadherin expression in dysadherin transfectants but did not affect E-cadherin expression in mock transfectants. Structural analysis of O-glycans released from the dysadherin chimera proteins indicated that a series of O-glycans with core 1 and 2 structures are attached to dysadherin, and their sialylation is remarkably inhibited by benzyl-α-GalNAc treatment. However, sialidase treatment of the cells did not affect calcium-dependent cell aggregation, which excluded the possibility that sialic acid itself is directly involved in cell-cell adhesion. We suggest that aberrant O-glycosylation in carcinoma cells inhibits stable expression of dysadherin and leads to the up-regulation of E-cadherin expression by an unknown mechanism, resulting in increased cell-cell adhesion. The carbohydrate-directed approach to the regulation of dysadherin expression might be a new strategy for cancer therapy.

AB - Recently, we identified dysadherin, a novel carcinoma-associated glycoprotein, and showed that overexpression of dysadherin in human hepatocarcinoma, PLC/PRF/5 cells could suppress E-cadherin-mediated cell-cell adhesion and promote tumor metastasis. The present study shows evidence that dysadherin is actually O-glycosylated. This was based on a direct carbohydrate composition analysis of a chimera protein of an extracellular domain of dysadherin fused to an Fc fragment of immunoglobulin. To assess the importance of O-glycosylation in dysadherin function, dysadherin-transfected hepatocarcinoma cells were cultured in a medium containing benzyl-α-GalNAc, a modulator of O-glycosylation. This treatment facilitated homotypic cell adhesion among dysadherin transfectants accompanied with morphological changes, indicating that the anti-adhesive effect of dysadherin was weakened. Modification of O-glycan synthesis also resulted in down-regulation of dysadherin expression and up-regulation of E-cadherin expression in dysadherin transfectants but did not affect E-cadherin expression in mock transfectants. Structural analysis of O-glycans released from the dysadherin chimera proteins indicated that a series of O-glycans with core 1 and 2 structures are attached to dysadherin, and their sialylation is remarkably inhibited by benzyl-α-GalNAc treatment. However, sialidase treatment of the cells did not affect calcium-dependent cell aggregation, which excluded the possibility that sialic acid itself is directly involved in cell-cell adhesion. We suggest that aberrant O-glycosylation in carcinoma cells inhibits stable expression of dysadherin and leads to the up-regulation of E-cadherin expression by an unknown mechanism, resulting in increased cell-cell adhesion. The carbohydrate-directed approach to the regulation of dysadherin expression might be a new strategy for cancer therapy.

KW - Benzyl-α-Ga1NAc

KW - Cell-cell adhesion

KW - Dysadherin

KW - E-cadherin

KW - O-glycosylation

UR - http://www.scopus.com/inward/record.url?scp=0037481949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037481949&partnerID=8YFLogxK

U2 - 10.1093/glycob/cwg065

DO - 10.1093/glycob/cwg065

M3 - Article

C2 - 12672699

AN - SCOPUS:0037481949

VL - 13

SP - 521

EP - 527

JO - Glycobiology

JF - Glycobiology

SN - 0959-6658

IS - 7

ER -